As a way of getting clinical trials "under way and successfully concluded," BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., has licensed its melanoma vaccine to the John P. Hussman Foundation for $100,000 up front, with up to $39 million in milestones.